In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis from Shenyang, north of China
Dear Editor, Tuberculosis (TB) has been a major health problem all over the world and China has the second highest prevalence of TB in the world. In China, multidrug-resistant (MDR) and extensively drug-resistant (XDR) M. tuberculosis strains represents a serious public health concern. [1] These have led to demand for new anti-tuberculosis drugs. Linezolid, the fi rst oxazolidinone antibiotics has been reported has the antituberculosis activity and may be used to treat MDR M. tuberculosis isolates. [2, 3] We tested the in vitro activity of linezolid against 61 clinical strains of M. tuberculosis isolated from Shenyang Chest Hospital using the agar proportion method. Linezolid was provided by Pfi zer (Zyvox ® ; Pfi zer Inc., New York, NY, USA). The drug susceptibility test results of the 61 strains were 21 (34.4%) susceptible, 7 (11.5%) monoresistant to INH, 3 (4.9%) polyresistant to INH and OFL, 20 (32.8%) MDR-TB and 10 (16.4%) XDR-TB [ Table 1 ]. The MICs of linezolid for the 61 strains are 0.125 -1 g/mL including 20 MDR-TB and 10 XDR-TB strains. This is lower than that of Prammananan et al. have reported. [4] And we did not fi nd the strains which were resistance to linezolid. There were no differences in MIC 50 of linezolid among the groups, which were 0.25 g/mL. Linezolid MIC 90 of XDR group was higher than that of the other groups, which were 0.5 g/m and 0.25 g/mL respectively [ Table 1 ] Our results suggest that linezolid has excellent activity against M. tuberculosis including MDR and XDR strains in China. Previously we have reported the clinical symptoms improved in three pulmonary TB patients (1 confi rmed and 2 suspected) treating with linezolid . [5] Because of the gastrointestinal and haematological adverse reactions of linezolid for long period used, we think that linezolid may be recommended for the treatment of XDR-TB with the other drugs in combination regimen with half of the routine doses. 
